Brief: Genfit Says Licensed Exclusive Rights Of ASK1 Inhibitor SRT-015 From Seal Rock Therapeutics

Genfit SA

31/05/2023 21:14

May 31 (Reuters) - Genfit Sa  GNFT.PA :
    * GENFIT FURTHER STRENGTHENS ITS ACLF FRANCHISE WITH A THIRD
CLINICAL-STAGE ASSET
    * NO MATERIAL IMPACT ON PREVIOUSLY GUIDED CASH RUNWAY:
COMPANY
FUNDING REMAINS SECURED UNTIL Q4 OF 2024
    * HAS LICENSED EXCLUSIVE RIGHTS OF ASK1 INHIBITOR SRT-015
FROM
SEAL ROCK THERAPEUTICS
    * FIRST-IN-HUMAN STUDY PLANNED IN SECOND HALF OF 2024 TO
SUPPORT A
PROOF-OF-CONCEPT STUDY IN ACLF PATIENTS AS EARLY AS 2025
    * GENFIT - SEAL ROCK THERAPEUTICS IS ELIGIBLE FOR PAYMENTS
UP TO
EUR 100 MILLION

Source text for Eikon:  ID:nGNE3kPlwf 
Further company coverage:  GNFT.PA 

 ((Reuters.Briefs@thomsonreuters.com;;))